Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Yasir Elamin

Psychiatry Reston, VA Medical Doctor

NPI 1003945346 CMS profile 226930

1850 Cameron Glen Dr, Suite #600, Reston, VA 20190

Open in the dashboard

General payments

$2,247

104 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Yasir Elamin of Reston, VA is reported in the CMS Open Payments database as having received $2,247 across 104 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 81st percentile of Psychiatry profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $219 6
2024 General $209 8
2023 General $164 7
2022 General $107 5
2021 General $69 4
2020 General $149 10
2019 General $1,330 64

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Yasir Elamin
  • Psychiatry median
  • Middle half of Psychiatry
  • National median

In program year 2025, general payments to Yasir Elamin were reported at $219. Among 14,155 Psychiatry profiles paid that year, the median was $180 and the middle half received between $58 and $685.

Show as a table
Year Yasir Elamin Psychiatry median Middle half National median
2019 $1,330 $184 $59–$605 $163
2020 $149 $119 $36–$372 $114
2021 $69 $143 $43–$576 $132
2022 $107 $153 $50–$590 $149
2023 $164 $170 $56–$651 $160
2024 $209 $179 $57–$673 $164
2025 $219 $180 $58–$685 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Janssen Pharmaceuticals, Inc $506 23 payments
  2. Alkermes, Inc. $397 19 payments
  3. Sunovion Pharmaceuticals Inc. $308 10 payments
  4. Otsuka America Pharmaceutical, Inc. $236 18 payments
  5. Teva Pharmaceuticals USA, Inc. $233 10 payments
  6. AbbVie, Inc. $156 7 payments
  7. Vanda Pharmaceuticals Inc. $120 4 payments
  8. Neurocrine Biosciences, Inc. $90 4 payments
  9. ITI, Inc. $53 3 payments
  10. Janssen Biotech, Inc. $45 1 payment
  11. Other $103 5 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $2,213 102 payments
  2. Education $34 2 payments
Products named General payments · program years 2019–2025
  1. SPRAVATO $404 11 payments
  2. INVEGA SUSTENNA $334 19 payments
  3. INVEGA TRINZA $328 18 payments
  4. LATUDA $308 10 payments
  5. AUSTEDO $233 10 payments
  6. VIVITROL $212 2 payments
  7. ARISTADA INITIO $185 17 payments
  8. ARISTADA Cns $185 17 payments
  9. ARISTADA Cns $185 17 payments
  10. ABILIFY MAINTENA $172 13 payments
  11. Other $1,111 67 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 26 drugs

Part D claims

1,625

Median for Psychiatry: 574

Drug cost

$332,411

Median for Psychiatry: $27,624

Branded share of claims

35.9%

Median for Psychiatry: 17%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Invega Sustenna Paliperidone Palmitate Brand 59 $178,736
Abilify Maintena Aripiprazole Brand 30 $89,829
Fanapt Iloperidone Brand 14 $31,378
Suboxone Buprenorphine Hcl/Naloxone Hcl Brand 373 $9,271
Aripiprazole Generic 164 $6,040
Clozapine Generic 66 $5,891
Paliperidone Er Paliperidone Brand 15 $1,408
Divalproex Sodium Er Divalproex Sodium Brand 34 $1,330
Olanzapine Generic 51 $1,266
Clomipramine Hcl Generic 25 $1,094

The 10 drugs with the highest cost, of 26 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 20,488 Part D prescribers listed as Psychiatry; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 4 billing codes

Paid by Medicare

$18,514

Medicare's payments for the services billed

Medicare patients

24

Average age 49

Services billed

203

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Ischemic heart disease 0%
Cancer 0%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

3 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
VRAYLAR
  • AbbVie, Inc. $89
$89 — —
FANAPT
  • Vanda Pharmaceuticals Inc. $73
$73 14 —
HETLIOZ
  • Vanda Pharmaceuticals Inc. $47
$47 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

104 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Psychiatry in Virginia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record